Obesity

Eli Lilly's Orforglipron Study in Adolescents with Obesity Underway

Eli Lilly is conducting a study to evaluate the efficacy and safety of orforglipron in adolescents with obesity or related comorbidities.

Eli Lilly's Tirzepatide Study Targets Adolescents with Obesity and Comorbidities

Eli Lilly is conducting a study to evaluate tirzepatide's effects on weight and cardiovascular risk in adolescents with obesity.

Roche to Present Phase II Data on Enicepatide and Petrelintide at ADA 2026

Roche will present new Phase II data for enicepatide and petrelintide in obesity at the ADA Scientific Sessions.

CVS Caremark to cover Foundayo and Zepbound, enhancing access for obesity treatment

CVS Caremark will cover Foundayo starting June 1 and Zepbound from October 1, allowing eligible patients to pay as low as $25 monthly.

Foundayo shows significant weight reduction in older adults with obesity in new analysis

Foundayo (orforglipron) demonstrated up to 13% body weight reduction in adults aged 65 and older with obesity.

Lilly's retatrutide shows significant weight loss in Phase 3 obesity trial

In the TRIUMPH-1 trial, retatrutide led to an average weight loss of 70.3 lbs (28.3%) over 80 weeks.

Roche Advances Obesity Portfolio with Promising Phase II Data on Enicepatide and Petrelintide

Roche presented late-breaking Phase II data showing significant efficacy and safety for enicepatide and petrelintide in weight management.

Roche Advances Obesity Portfolio with Promising Phase II Data for Enicepatide and Petrelintide

Roche presented late-breaking Phase II data showing significant efficacy and safety for enicepatide and petrelintide in weight management.

Pfizer's Berobenatide Shows Promising Phase 2b Results for Monthly Dosing in Obesity Management

Lilly's Retatrutide Shows Significant Weight Loss and Pain Reduction in TRIUMPH-1 Trial

In the TRIUMPH-1 trial, retatrutide led to an average weight loss of 70.3 lbs and significant reductions in knee osteoarthritis pain.